NASDAQ$DAWN
Day One Biopharmaceuticals Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Day One Biopharmaceuticals reported its fourth quarter and full year 2024 financial results, highlighting strong OJEMDA net product revenues and corporate progress.
Day One Biopharmaceuticals achieved significant growth in Q4 2024 with OJEMDA net product revenues reaching $29.0 million, contributing to a full year total of $57.2 million. The company ended 2024 with a strong cash position of $531.7 million, indicating a solid financial foundation for future growth and mission realization.
- OJEMDA net product revenues for Q4 2024 were $29.0 million, marking a 44% increase from Q3 2024.
- The company ended 2024 with $531.7 million in cash, cash equivalents, and short-term investments.
- OJEMDA received Exclusively Pediatric designation, reducing its Medicaid and 340B minimum rebate percentage.
- Day One advanced enrollment in the global, pivotal Phase 3 FIREFLY-2 clinical trial, with full enrollment expected in the first half of 2026.
Headline financials
Revenue & EPS history
Day One · Revenue · Quarterly
$131M
Forward guidance
Day One Biopharmaceuticals is focused on continued growth for OJEMDA, advancing its clinical pipeline, and maintaining a strong financial position.
Tailwinds
- Full enrollment in the global, pivotal Phase 3 FIREFLY-2 clinical trial is expected in the first half of 2026.
- The company aims for long-term, durable growth with OJEMDA as its foundation.
- Continued progress in the DAY301 clinical trial, having cleared the first dose cohort.
- Strong balance sheet provides a solid financial foundation.
- Commitment to developing and commercializing targeted therapies for life-threatening diseases across all ages.
Headwinds
- Continued approval for OJEMDA's indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
- Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ significantly.
- Risks include the ability to obtain and retain regulatory approval for product candidates.
- Potential impact of global business or macroeconomic conditions, including inflation and interest rate volatility.
- Geopolitical conflicts and regulatory developments could affect operations.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
-1.4%
Avg return
Earnings day
-2.1%
Avg return
5 days after
+1.2%
Avg return
30 days after
45%
9 / 20 earnings
Positive
+23.6%
Q2 2022
Best reaction
-16.6%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -9.2% | -13.9% | +78.0% | |
| Q3 2025 | +0.0% | +3.7% | +34.8% | |
| Q2 2025 | -15.4% | -14.2% | +9.7% | |
| Q1 2025 | -9.6% | -5.9% | +2.9% | |
| Q4 2024 | -16.5% | -30.2% | -31.7% | |
| Q3 2024 | +2.6% | +3.2% | -2.9% | |
| Q2 2024 | -6.8% | -9.4% | -11.0% | |
| Q1 2024 | -0.5% | -6.8% | -23.9% | |
| Q4 2023 | +14.5% | +15.0% | +4.0% | |
| Q3 2023 | -3.1% | -11.1% | -3.7% | |
| Q2 2023 | +1.3% | +4.3% | +9.6% | |
| Q1 2023 | +12.7% | +10.3% | +7.3% | |
| Q4 2022 | +5.3% | -4.2% | -32.8% | |
| Q3 2022 | +2.7% | +10.6% | +14.3% | |
| Q2 2022 | +23.6% | +18.9% | +24.4% | |
| Q1 2022 | +8.5% | +21.8% | -6.1% | |
| Q4 2021 | +3.7% | -3.8% | -6.9% | |
| Q3 2021 | -9.2% | -15.7% | -31.7% | |
| Q2 2021 | -16.6% | -7.6% | -5.2% | |
| Q4 2020 | -16.6% | -7.6% | -5.2% | |
| Q1 2021 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro